...
首页> 外文期刊>Brain research >The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
【24h】

The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.

机译:5-HT(1A)受体刺激对多巴胺受体介导的致敏半帕金森氏大鼠中异常不自主运动和旋转的不同作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Serotonin 1A receptor (5-HT(1A)R) agonists have emerged as valuable supplements to l-DOPA therapy, demonstrating that they can decrease side effects and enhance motor function in animal models of Parkinson's disease (PD) and human PD patients. The precise mechanism by which these receptors act remains unknown and there is limited information on how 5-HT(1A)R stimulation impacts striatal dopamine (DA) D1 receptor (D1R) and D2 receptor (D2R) function. The current study examined the effects of 5-HT(1A)R stimulation on DA receptor-mediated behaviors. Male Sprague-Dawley rats were rendered hemiparkinsonian by unilateral 6-OHDA lesions and primed with the D1R agonist SKF81297 (0.8 mg/kg, i.p.) in order to sensitize DA receptors. Using a randomized within subjects design, rats received a first injection of: Vehicle (dH(2)O) or the 5-HT(1A)R agonist +/-8-OH-DPAT (0.1 or 1.0 mg/kg, i.p.), followed by a second injection of: Vehicle (dimethyl sulfoxide), the D1R agonist SKF81297 (0.8 mg/kg, i.p.), the D2R agonistquinpirole (0.2 mg/kg, i.p.), or l-DOPA (12 mg/kg+benserazide, 15 mg/kg, i.p.). On test days, rats were monitored over a 2-h period immediately following the second injection for abnormal involuntary movements (AIMs), analogous to dyskinesia observed in PD patients, and contralateral rotations. The present findings indicate that 5-HT(1A)R stimulation reduces AIMs induced by D1R, D2R and l-DOPA administration while its effects on DA agonist-induced rotations were receptor-dependent, suggesting that direct 5-HT(1A)R and DA receptor interactions may contribute to the unique profile of 5-HT(1A)R agonists for the improvement of PD treatment.
机译:血清素1A受体(5-HT(1A)R)激动剂已成为1-DOPA治疗的有价值的补充剂,表明它们可以减少帕金森氏病(PD)和人类PD患者动物模型中的副作用并增强运动功能。这些受体发挥作用的确切机制仍是未知的,关于5-HT(1A)R刺激如何影响纹状体多巴胺(DA)D1受体(D1R)和D2受体(D2R)功能的信息有限。当前的研究检查了5-HT(1A)R刺激对DA受体介导的行为的影响。通过单侧6-OHDA损伤使雄性Sprague-Dawley大鼠偏瘫并用D1R激动剂SKF81297(0.8 mg / kg,i.p.)灌注以敏化DA受体。使用受试者内的随机设计,大鼠首次注射:媒介物(dH(2)O)或5-HT(1A)R激动剂+/- 8-OH-DPAT(0.1或1.0 mg / kg,腹膜内) ,然后第二次注射:媒介物(二甲亚砜),D1R激动剂SKF81297(0.8 mg / kg,腹腔注射),D2R激动剂喹吡罗(0.2 mg / kg,腹腔注射)或l-DOPA(12 mg / kg +苄丝肼) ,15 mg / kg,ip)。在测试日,在第二次注射后立即在2小时内监测大鼠的异常非自愿运动(AIM),类似于在PD患者中观察到的运动障碍和对侧旋转。目前的发现表明5-HT(1A)R刺激降低了由D1R,D2R和1-DOPA给药诱导的AIM,而其对DA激动剂诱导的旋转的作用是受体依赖性的,表明直接5-HT(1A)R和DA受体的相互作用可能有助于5-HT(1A)R激动剂的独特特性,以改善PD治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号